RESEARCH TRIANGLE PARK, N.C. – Biogen Idec produces biotech medicines for patients with multiple sclerosis and hemophilia. And, lately, the company also has produced solid revenue streams and job opportunities in North Carolina.

Biogen Idec has grown revenue and employment by more than 50 percent over the past three years and is expecting more growth in 2015, according to the company on Friday.

The jobs include positions at all levels in the organization, and includes manufacturing associates who run the manufacturing processes, to engineers and quality assurance technicians who help keep the facility running.  Biogen has roles available both in the biologics facility in Morrisville and the solid dose facility in Durham.

The news comes as the company reported full-year and fourth quarter 2014 results, including full-year revenues of $9.7 billion, a 40 percent increase versus 2013.  Non-GAAP net income attributable to Biogen Idec for the year was $3.3 billion, an increase of 54% versus the year prior.

“2014 was a remarkable year for our company and the patients we serve,” said Biogen Idec’s CEO George Scangos. “The growth of TECFIDERA in world markets, the improved performance of TYSABRI, and our entry into the treatment of hemophilia demonstrated our strength as a commercial organization while benefiting patients in many countries around the world. 2015 promises to be another exciting year,” Dr. Scangos continued.

Scangos said the company’s focus on novel biology to seek treatments for challenging diseases has shaped its pipeline and business strategy, and will continue to do so in the future.

Commitment to STEM and Talent Pool

Citizen Schools, a national nonprofit organization that partners with public middle schools to expand the learning day for underserved students, also announced this week a new Biogen Idec Foundation grant to support its science, technology, engineering, and math (STEM) programs, and named the Biogen Idec Foundation its first National Innovation Partner.

As a National Innovation Partner, the Biogen Idec Foundation will extend the innovative work of the Biogen Idec Community Lab from Massachusetts to North Carolina and will invest $1.5 million in Citizen Schools over the next three years to scale STEM programs. Since 2008, 37 Biogen Idec employees have taught nine apprenticeships in Massachusetts and North Carolina.

Biogen Idec is based in Cambridge, Mass. It is one of the North Carolina’s largest biotechnology companies with 1,300 employees in the Research Triangle Park.